Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Volitionrx Ltd (VNRX)

Volitionrx Ltd (VNRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 33,034
  • Shares Outstanding, K 122,802
  • Annual Sales, $ 1,230 K
  • Annual Income, $ -26,970 K
  • EBIT $ -23 M
  • EBITDA $ -22 M
  • 60-Month Beta 1.26
  • Price/Sales 28.59
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.22
  • Most Recent Earnings $-0.04 on 11/13/25
  • Next Earnings Date 03/30/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 589.94% (+12.21%)
  • Historical Volatility 78.98%
  • IV Percentile 85%
  • IV Rank 42.85%
  • IV High 1,072.29% on 04/10/25
  • IV Low 228.31% on 11/12/25
  • Expected Move (DTE 5) 0.0425 (15.74%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 8
  • Volume Avg (30-Day) 20
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 828
  • Open Int (30-Day) 622
  • Expected Range 0.2275 to 0.3125

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.05
  • Number of Estimates 2
  • High Estimate -0.04
  • Low Estimate -0.05
  • Prior Year -0.06
  • Growth Rate Est. (year over year) +16.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2660 +1.13%
on 12/12/25
0.3950 -31.90%
on 11/13/25
-0.1017 (-27.43%)
since 11/12/25
3-Month
0.2660 +1.13%
on 12/12/25
0.7400 -63.65%
on 09/30/25
-0.3871 (-59.00%)
since 09/12/25
52-Week
0.2660 +1.13%
on 12/12/25
0.9400 -71.38%
on 06/23/25
-0.3410 (-55.90%)
since 12/12/24

Most Recent Stories

More News
Volition Solves Liquid Biopsy's "Needle in a Haystack" Problem; Achieves 180-fold (18,000%) Enrichment

HENDERSON, Nev. , Dec. 11, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces preprint availability of a new manuscript entitled...

VNRX : 0.2690 (-6.37%)
Volition Announces Two Abstracts were Presented at the North America Conference on Lung Cancer

HENDERSON, Nev., , December 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of two abstracts at the...

VNRX : 0.2690 (-6.37%)
VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of Sepsis

HENDERSON, Nev. , Dec. 4, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the inclusion of its Nu.Q® NETs H3.1 assay...

VNRX : 0.2690 (-6.37%)
VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use

HENDERSON, Nev. , Nov. 25, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the first sale of its Nu.Q® Cancer assays...

VNRX : 0.2690 (-6.37%)
VolitionRx Limited Announces Third Quarter 2025 Financial Results and Business Update

Conference call to discuss financial and operational results scheduled for Friday, November 14 at 8:30 a.m. U.S. Eastern Time

VNRX : 0.2690 (-6.37%)
VolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update

Conference call to take place on Friday, November 14 at 8:30 a.m. U.S. Eastern Time

VNRX : 0.2690 (-6.37%)
Volition Donates Nu.Q® Vet Cancer Tests to HOPE Animal-Assisted Crisis Response Dogs

HENDERSON, Nev. , Oct. 17, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), and its subsidiary, Volition Veterinary Diagnostics Development LLC, in line with their corporate...

VNRX : 0.2690 (-6.37%)
VolitionRx Limited Announces Pricing of $6.0 Million Underwritten Public Offering of Common Stock and Common Stock Warrants

HENDERSON, Nev. , Oct. 10, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today the pricing of an underwritten...

VNRX : 0.2690 (-6.37%)
VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock and Common Stock Warrants

HENDERSON, Nev. , Oct. 9, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it is proposing to...

VNRX : 0.2690 (-6.37%)
Volition Sponsors Upcoming GenomeWeb Webinar

HENDERSON, Nev. , Oct. 2, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the sponsorship of a GenomeWeb...

VNRX : 0.2690 (-6.37%)

Business Summary

Volition RX Ltd is a life sciences company engaged in developing a range of blood-based epigenetic cancer diagnostic tests. Its tests are designed to detect the nucleosome patterns that are specific to cancer in the blood, and identify some of the major nucleosome varieties that differ between cancer...

See More

Key Turning Points

3rd Resistance Point 0.3238
2nd Resistance Point 0.3117
1st Resistance Point 0.2903
Last Price 0.2690
1st Support Level 0.2568
2nd Support Level 0.2447
3rd Support Level 0.2233

See More

52-Week High 0.9400
Fibonacci 61.8% 0.6825
Fibonacci 50% 0.6030
Fibonacci 38.2% 0.5235
Last Price 0.2690
52-Week Low 0.2660

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar